Ptc Therapeutics (PTCT) Total Current Liabilities (2012 - 2026)
Ptc Therapeutics (PTCT) posted quarterly Total Current Liabilities of $771.1 million for Q2 2026, up 22.82% year-over-year from $627.8 million in Q2 2025, and down 16.52% quarter-over-quarter from $923.6 million in Q1 2026.
Ptc Therapeutics (PTCT) Total Current Liabilities (2012 - 2026) Analysis & Trends
Ptc Therapeutics' Total Current Liabilities history runs 15 years deep, the most recent figure standing at $771.1 million for Q2 2026.
- In Q2 2026, Total Current Liabilities rose 22.82% year-over-year to $771.1 million; the TTM figure through Jun 2026 stood at $771.1 million (up 22.82% YoY), while the FY2025 annual figure was $968.4 million, up 66.69% from the prior year.
- Total Current Liabilities for Q2 2026 stood at $771.1 million, down from $923.6 million in the prior quarter.
- The five-year high for Total Current Liabilities was $968.4 million in Q4 2025, with the low at $406.2 million in Q4 2022.
- The 5-year median for Total Current Liabilities is $588.2 million (2024), against an average of $611.8 million.
- Peak annual rise in Total Current Liabilities reached 95.0% in 2022, while the deepest fall reached 20.24% in 2022.
- Ptc Therapeutics' Total Current Liabilities stood at $406.2 million in 2022, then jumped by 48.46% to $603.1 million in 2023, then declined by 3.67% to $581.0 million in 2024, then soared by 66.69% to $968.4 million in 2025, then decreased by 20.38% to $771.1 million in 2026.
- Business Quant data shows PTCT's Total Current Liabilities at $771.1 million in Q2 2026, $923.6 million in Q1 2026, and $968.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Ptc Therapeutics | 5.97 Bn | 3.75 Bn | 340.60 Mn | 771.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 771.07 Mn |
| Mar 31, 2026 | 923.60 Mn |
| Dec 31, 2025 | 968.43 Mn |
| Sep 30, 2025 | 866.25 Mn |
| Jun 30, 2025 | 627.81 Mn |
| Mar 31, 2025 | 595.39 Mn |
| Dec 31, 2024 | 580.98 Mn |
| Sep 30, 2024 | 610.71 Mn |
| Jun 30, 2024 | 609.80 Mn |
| Mar 31, 2024 | 574.55 Mn |
| Dec 31, 2023 | 603.10 Mn |
| Sep 30, 2023 | 492.12 Mn |
| Jun 30, 2023 | 476.34 Mn |
| Mar 31, 2023 | 441.63 Mn |
| Dec 31, 2022 | 406.24 Mn |
| Sep 30, 2022 | 420.08 Mn |
| Jun 30, 2022 | 567.37 Mn |
| Mar 31, 2022 | 476.78 Mn |
| Dec 31, 2021 | 509.35 Mn |
| Sep 30, 2021 | 465.26 Mn |